Hormone Refractory Prostate Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic NeoplasmsIntervention: Drug: Radium-223 dichloride (BAY88-8223)Sponsor: BayerActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2012 Category: Research Source Type: clinical trials
